ONCOTHO-ICU : Survival prognostic factors among lung cancer patients admitted to ICU between 2021 and 2023.
Abstract
Background
The admission of patients with lung cancer to the intensive care unit (ICU) remains challenging due to historically poor outcomes. However, recent advances in oncological treatments and ICU care call for new evaluation of prognostic factors and long-term survival in this population.
Objectives
Assess 6-month survival and identify prognostic factors among patients with an active lung cancer admitted to the ICU.
Methods
We conducted a retrospective, multicentric study including all patients with lung cancer admitted to ICU, excluding intermediate care unit admission, in Lyon between 2021 and 2023. Clinical, oncological, and ICU-related variables were analyzed to identify factors associated with 6-month survival.
Results
281 patients were included in the study. ICU and 6-month survival remained poor (respectively 68% and 33.1%). SOFA score, respiratory failure and sepsis were independently associated with mortality. Conversely, a longer interval between cancer diagnosis and ICU admission was associated with improved prognosis. Performance status at 6 months suggested a preserved quality of life in most survival patients.
Conclusion
ICU admission for patients with bronchopulmonary cancer remains associated with a low 6-month survival rates. We highlighted several prognostic factors consistent with previous studies, but larger prospective studies are needed to further investigate these findings.